Laromestrocel
AssetAlso Longeveron Mesenchymal Stem Cells, LMSCs, Lomecel-B, Allogenic Longeveron Human Mesenchymal Stem Cells
Allogeneic mesenchymal stem cells repair, regenerate or replace damaged or diseased cells.
- Stage
- Phase 2
- Modality
- Cell therapy
- Target
- Inflammation
- 5
- Indications
- 4
- Trials
- 1
- Developer
Indications
5Aging frailty
Phase 2, Completed, NCT03169231, clinicaltrials.gov, 7 Oct 2026
Alzheimer's disease
Phase 2, longeveron.com, 10 Oct 2026
Hypoplastic left heart syndrome
Phase 2, longeveron.com, 10 Oct 2026
2 more
In the full profile
- Targets and what it contains2
- Owner and partners2
- Trials4
- Evidence for its targets3
- Competitors9
- Aging relevance3
- Signals1
Every asset’s record: target, stage, trials and the evidence behind it.